Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-09-17
2010-11-02
Davis, Zinna N (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S157000
Reexamination Certificate
active
07825131
ABSTRACT:
The present invention relates to compounds having the structure (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.
REFERENCES:
patent: 3202661 (1965-08-01), Brust et al
patent: 4232027 (1980-11-01), Turk et al.
patent: 0 421 456 (1991-04-01), None
patent: 652218 (1995-05-01), None
patent: 2002 371078 (2002-12-01), None
patent: WO 92/17452 (1992-10-01), None
patent: WO97/21701 (1997-06-01), None
patent: WO99/09983 (1999-03-01), None
patent: WO00/34244 (2000-06-01), None
patent: WO 00/34278 (2000-06-01), None
patent: WO 02/092076 (2002-11-01), None
Bhat et al, Chemical Abstracts, vol. 104, Accession No. 168331, 1986.
Neelima et al, Zeitschrift fuer Naturforschung, Teil B, 1985, 40B(7), pp. 990-995.
Supplementary European Search Report, Jul. 2009.
Neelima, Bhart et al. Zeitschrift fuer Naturforschung Teil B: Anorganische Chemie, Organische Chemie, vol. 40 No. 7, 1985, pp. 990-995.
Bergman Jeffrey M.
Dinsmore Christopher J.
Daniel Mark R.
Davis Zinna N
Merck Sharp & Dohme Corp.
Parr Richard S.
Struse Heidi M.
LandOfFree
Quinoline potassium channel inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Quinoline potassium channel inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinoline potassium channel inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4162626